1. A. The following controlled substances are included in Schedule V:

   1. (1) any compound, mixture or preparation that contains the following limited quantities of any of the following narcotic drugs, and that also contains one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

      1. (a) not more than two hundred milligrams of codeine, or any of its salts, per one hundred milliliters or per one hundred grams;
      2. (b) not more than one hundred milligrams of dihydrocodeine, or any of its salts, per one hundred milliliters or per one hundred grams;
      3. (c) not more than one hundred milligrams of ethylmorphine, or any of its salts, per one hundred milliliters or per one hundred grams;
      4. (d) not more than two and five-tenths milligrams of diphenoxylate and not less than twenty-five micrograms of atropine sulfate per dosage unit; or
      5. (e) not more than one hundred milligrams of opium per one hundred milliliters or per one hundred grams; and

   2. (2) any compound, mixture or preparation that contains any detectable quantity of pseudoephedrine, its salts or its optical isomers, or salts of its optical isomers. A compound, mixture or preparation as specified in this paragraph shall be dispensed, sold or distributed only by a licensed pharmacist or pharmacist intern or a registered pharmacy technician. Unless pursuant to a valid prescription, a person purchasing, receiving or otherwise acquiring the compound, mixture or preparation shall:

      1. (a) produce a driver's license or other government-issued photo identification showing the date of birth of the person;
      2. (b) sign a written log, receipt or other program or mechanism indicating the date of the transaction, name of the person, driver's license number or government-issued identification number, name of the pharmacist, pharmacist intern or pharmacy technician conducting the transaction, the product sold and the total quantity, in grams or milligrams, of pseudoephedrine purchased; and
      3. (c) be limited to no more than nine grams of any product, mixture or preparation within a thirty-day period.

2. B. The board may by regulation exempt any compound, mixture or preparation containing any depressant or stimulant substance enumerated in Schedules III, IV or V from the application of the Controlled Substances Act if:

   1. (1) the compound, mixture or preparation contains one or more active medicinal ingredients not having a depressant or stimulant effect on the central nervous system; and
   2. (2) such ingredients are included in such combinations, quantity, proportion or concentration as to vitiate the potential for abuse of the substances which do have a depressant or stimulant effect on the nervous system.
3. C. The board may, by rule, exempt a product containing pseudoephedrine from Schedule V if the board determines that the product is formulated as to effectively prevent the conversion of pseudoephedrine into methamphetamine.
4. D. The board shall monitor prices charged for compounds, mixtures and preparations that contain pseudoephedrine and may adopt rules to prevent unwarranted price increases as a result of compliance with this section.

History: 1953 Comp., § 54-11-10, enacted by Laws 1972, ch. 84, § 10; 2006, ch. 16, § 2.

ANNOTATIONS

The 2006 amendment, effective July 1, 2006, added Paragraph (2) of Subsection A to include pseudoephedrine as a controlled substance; permitted only licensed pharmacists, interns or technicians to sell pseudoephedrine; limited the amount of pseudoephedrine that may be sold to a purchaser; and unless pursuant to a prescription, required persons who purchase pseudoephedrine to provide identification and to sign a log; added Subsection C to provide that the board may exempt a product containing pseudoephedrine from Schedule V if the board determines the product is formulated to prevent the conversion of the product to methamphetamine; and added Subsection D to provide that the board shall monitor prices charged for products with pseudoephedrine and adopt rules to prevent unwarranted price increases.